Literature Review 7 pages

6/13/20, 10:46 AMEBSCOhost

Page 1 of 3https://web-a-ebscohost-com.libproxy.hbu.edu/ehost/delivery?sid=…6sid%3d06d51608-e028-4713-ade6-9471c3ac80c4%2540sdc-v-sessmgr01

Title:

Authors:

Source:

Document Type: Subject Terms:

Author-Supplied Keywords:

Abstract:

Record: 1

Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis. Bohn, Barbara [email protected] Schöfl, Christof Zimmer, Vincent Hummel, Michael Heise, Nikolai Siegel, Erhard Karges, Wolfram Riedl, Michaela Holl, Reinhard W. Cardiovascular Diabetology. 5/3/2016, Vol. 15, p1-17. 17p. 1 Diagram, 3 Charts, 2 Graphs. Article *MYOCARDIAL infarction treatment *NON-insulin-dependent diabetes treatment *PATIENT management *QUALITY of life MYOCARDIAL infarction diagnosis Guideline adherence Myocardial infarction Secondary prevention Stroke Type 2 diabetes Background: To analyze whether medical care is in accordance with guidelines for secondary prevention of myocardial infarction (MI), or stroke in patients with type 2 diabetes from Germany and Austria. Methods: 29,325 patients (≥20 years of age) with type 2 diabetes and MI, or stroke, documented between 2006 and 2015 were selected from the Diabetes-Patienten-Verlaufsdokumentation database. We analyzed medication, clinical characteristics, and lifestyle factors according to national secondary prevention guidelines in patients with MI, or stroke, separately. Results: HbA1C <7.5 % was achieved in 64.9 % (MI), and in 61.1 % (stroke) of

1,2

3

4,5

6

7

8

9

10

1,2

6/13/20, 10:46 AMEBSCOhost

Page 2 of 3https://web-a-ebscohost-com.libproxy.hbu.edu/ehost/delivery?sid=…6sid%3d06d51608-e028-4713-ade6-9471c3ac80c4%2540sdc-v-sessmgr01

Author Affiliations:

patients. LDL <100 mg/dl was documented in 56.2 % (MI), and in 42.2 % (stroke). Non-smoking was reported in 92.0 % (MI), and in 93.1 % (stroke), physical activity in 9.6 % (MI), and 5.5 % (stroke). Target values of blood pressure (<130/80 mmHg in MI, 120/70- 140/90 in stroke) were reached in 67.0 % (MI), and in 89.9 % (stroke). Prescription prevalence of inhibitors of platelet aggregation (IPA) was 50.7 % (MI), and 31.7 % (stroke). 57.0 % (MI), and 40.1 % (stroke) used statins, 65.1 % (MI), and 65.8 % (stroke) used any type of antihypertensives, and ACE inhibitors were prescribed in 49.7 % (MI), and 41.3 % (stroke). A body mass index (BMI) <27 kg/m² and the use of beta blockers were only recommended in subjects with MI. Of the patients with MI, 32.0 % had a BMI <27 kg/m², and 59.5 % used beta blockers. Conclusions: Achievement of treatment goals in secondary prevention of MI, or stroke in subjects with type 2 diabetes needs improvement. Target goals were met more frequently in patients with MI compared to subjects with stroke. Especially the use of IPA was very low in patients with stroke. There remains great potential to reduce the risk of repeated macrovascular events and premature death, as well as to increase patients' quality of life. [ABSTRACT FROM AUTHOR] Copyright of Cardiovascular Diabetology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) Institute of Epidemiology and Medical Biometry, ZIBMT, University

of Ulm, Albert-Einstein-Allee 41, 89081 Ulm, Germany German Center for Diabetes Research (DZD), Munich-

Neuherberg, Germany Division of Endocrinology and Diabetes, Department of Medicine I,

University Hospital Erlangen, Friedrich-Alexander-University, Erlangen-Nuremberg, Germany Department for Internal Medicine, Protestant Hospital

Zweibrücken, Zweibrücken, Germany Department of Medicine II, Saarland University Medical Center,

1

2

3

4

5

6/13/20, 10:46 AMEBSCOhost

Page 3 of 3https://web-a-ebscohost-com.libproxy.hbu.edu/ehost/delivery?sid=…6sid%3d06d51608-e028-4713-ade6-9471c3ac80c4%2540sdc-v-sessmgr01

ISSN: DOI:

Accession Number: Database:

Homburg, Germany Specialized Diabetes Practice Rosenheim & Institute of Diabetes

Research, Helmholtz Center Munich, Munich, Germany Alb Fils Kliniken, Helfenstein Clinic, Geislingen, Germany Department of Internal Medicine, St. Josefs Hospital, Heidelberg,

Germany Division of Endocrinology and Diabetes, RWTH Aachen University,

Aachen, Germany Division of Endocrinology and Metabolism, Department of Internal

Medicine III, Medical University of Vienna, Vienna, Austria 1475-2840 10.1186/s12933-016-0391-8 115169282 Academic Search Complete

6

7

8

9

10